SSSD 2021
PROGRAM
Thursday March 11
09.00-09.10 Welcome
Diabetes classification and precision medicine
(chairs: Kåre I. Birkeland, Tore Julsrud Berg)
09.10-09.40 Pål Njølstad, Bergen: Monogenic diabetes
09.40-10.20 Emma Ahlqvist, Malmö: New phenotypic classification of diabetes
10.20-11.00 Markku Laakso, Kuopio: New genetic classification of diabetes
11.00-11.15 Break
11.15-12.30 Oral abstract presentations
(chairs: Bjørn Olav Åsvold, Malin Flodström Tullberg)
O1: Ulf Hannelius: Precision Medicine for Type 1 Diabetes - The Influence of HLA, Dose and
Administration Route on the Effect of GAD-specific Immunotherapy
O2: Johnny Ludvigsson: Intralymphatic glutamic acid decarboxylase in recent onset Type 1 diabetes: a
double-blind randomized placebo-controlled Phase IIb trial (DIAGNODE-2)
O3: Agnes Andersson Svärd: HLA-DRA1 intron triSNP haplotypes affect the risk of islet autoantibodies
in children with increased genetic risk for autoimmune type 1 diabetes
O4: Björn Andersson: Characterization of the human virome in a childhood Type 1 diabetes cohort
O5: Dina Mansour Aly: Genetics of Kidney complications in diabetes subtypes
O6: Shilan Seyed Ahmadi: Risk Factors for Nephropathy in Persons with Type 1 Diabetes: A Population-
Based Study
O7: Eirik Søfteland: Sexual dysfunction in Norwegian women with type 1 diabetes: a cross-sectional
study
O8: Mari Sørstrand Æsøy: Sexual dysfunction in women with type 1 diabetes is associated with impaired
autonomic function
12.40-13.40 Lunch break with symposium arranged by Novo Nordisk
Trond Methi: Diabetes and the Brain - The mysteries of the brain, consciousness, free will, cognitive
function, artificial intelligence, appetite regulation, metabolism and sleep
The Swedish Child Diabetes Foundation Awards
(chair: Johnny Ludvigsson)
13.40-14.20 Swedish Child Diabetes Foundation's Johnny Ludvigsson Nordic Prize
Per-Ola Carlsson, Uppsala
14.20-14.45 The Swedish Child Diabetes Foundation's Johnny Ludvigsson Prize to a Young Swedish Scientist
lecture
Araz Rawshani, Göteborg
14.45-15.00 Break
Diabetes epidemiology
(chairs: Lars Christian Stene, Sofia Carlsson)
15.00-15.45 Ed Gregg, London: New Divides, Directions, and Demands in the Global Type 2 Diabetes Epidemic
15.45-16.20 Oral abstract presentations
O9: Paz LD Ruiz: Epidemiology of covid-19 in people with diabetes in Norway: a nationwide register-
based study of infection, hospitalization, vaccination and mortality
O10: Vera Vik Bjarkø: The prevalence and cardiovascular risk profile of undiagnosed diabetes in a
Norwegian population. The HUNT4 Survey
O11: Katharina Herzog: Alterations in biomarkers of carbohydrate and lipid metabolism up to 20 years
before the diagnosis of type 1 diabetes – findings from the AMORIS cohort
O12: Emma Hedlund: Month of birth and risk of developing type 1 diabetes among children in the
Swedish national diabetes cohort, the BDD-study
16.20-16.30 Break
Novo Nordisk Foundation Lecture
16.30-16.40 Introduction by Anna Krook, Novo Nordisk Foundation
16.40-17.35 Kåre I. Birkeland, Oslo: Type 2 diabetes, insulin resistance and cardiovascular disease
17.50-18.30 The annual SSSD general assembly
Friday March 12
Obesity and metabolic syndrome
(chairs: Jørn Sagen, Hanne Løvdal Gulseth)
08.30-09.00 Mikael Rydén, Stockholm: Some novel aspects on white adipose tissue function in mice and men
09.00-09.30 Dag Hofsø, Tønsberg: When and how should we treat patients with type 2 diabetes with bariatric
surgery?
09.30-10.00 Simon Dankel, Bergen: Why does obesity lead to insulin resistance and diabetes?
10.00-10.15 Break
Diabetes technology
(chairs: Sverre Christiansen, Stine L. Fougner)
10.15-10.45 Kirsten Nørgaard, Copenhagen: Evidence and experience with self-adjusting insulin pumps
Gestational diabetes
(chairs: Sverre Christiansen, Stine L. Fougner)
10.45-11.15 Elisabeth Mathiesen, Copenhagen: Insulin treatment in gestational diabetes
11.15-12.05 Oral abstract presentations
(chairs: Sondre V. Meling, Esben Søndergaard)
O13: Nicolas Fragoso-Bargas: Epigenome-wide association study (EWAS) of insulin resistance in
pregnancy
O14: Stine L. Fougner: The impact of gestational diabetes mellitus on pregnancy complications and
outcome in women with polycystic ovary syndrome
O15: Björn Morén: Small droplets and droplet cluster formation in human adipocytes – a possible site for
lipid transfer and lipid metabolism
O16: Mette Louise B.G. Kjærulff: Effect of intermittent fasting on insulin resistance and substrate
metabolism of the heart
O17: Camilla Skoglund: Increase of neutrophil extracellular traps as well as extracellular mitochondrial
and nuclear DNA in newly diagnosed type 1 diabetes children
O18: Amaya Lopez-Pascual: CEBPG, a novel beta cell transcription factor influences insulin secretion
12.15-13.15 Lunch break with symposium arranged by AstraZeneca
Peter Rossing, Steno Diabetes Center Copenhagen: Diabetes and chronic kidney disease
13.15-14.00 Oral abstract presentations
(chairs: Stine L. Fougner, Virginia Stone)
O19: Chandra Yogal: Prevalence of type 2 diabetes and risk factors among women in rural Nepal
O20: Sara Juul Mansachs: Neuropeptide Y autoantibodies in Danish Type 1 Diabetes patients
O21: Hugo Barcenilla: High-dimensional single cell analysis of immune populations in recent onset type 1
diabetes patients receiving GAD-alum injection into the lymph node
O22: Anna-Maria Lampousi: Dietary factors and risk of islet autoimmunity and type 1 diabetes: a
systematic review and meta-analysis
O23: Jessica Edstorp: Tobacco use and interaction with HLA genotypes in the risk of latent autoimmune
diabetes in adults: results from two population-based studies
Genetics
(chairs: Lars Christian Stene, Johan Fernø)
14.00-14.45 Marcel den Hoed, Uppsala: Functional follow-up of GWAS findings
14.45-15.00 Break
Awards
(chairs: Bjørn Olav Åsvold, Elin Pettersen Sørgjerd)
15.00-15.50 Knud Lundbæk Award lecture
Åke Lernmark, Malmö: Dissecting the etiology of autoimmune (type 1) diabetes
15.50-16.20 SSSD Young Investigator Awards
Simon Lecoutre: Glutamine links obesity to inflammation in human white adipose tissue
Ning Liang: Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via
activation of PPARα